Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization

Overview

Journal Pathogens

Date 2021 Feb 12

PMID 33573221

Citations 45

Authors

Yongjun Sui

Yonas Bekele

Jay A Berzofsky

Affiliations

Soon will be listed here.

Abstract

Both SARS-CoV-2 infections and vaccines induce robust immune responses. Current data suggested that high neutralizing antibody titers with sustained Th1 responses might correlate with protection against viral transmission and disease development and severity. In addition, genetic and innate immune factors, including higher levels of type I interferons, as well as the induction of trained immunity and local mucosal immunity also contribute to lower risk of infection and amelioration of disease severity. The identification of immune correlates of protection will facilitate the development of effective vaccines and therapeutics strategies.

Citing Articles

COVID-19 pneumonia in lung transplant recipients: understanding risk factors and treatment outcomes in Japan.

Watanabe T, Hirama T, Akiba M, Watanabe T, Watanabe Y, Oishi H Clin Exp Med. 2024; 24(1):123.

PMID: 38856777 PMC: 11164722. DOI: 10.1007/s10238-024-01388-y.

Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.

Li J, Hsu K, Howe S, Hoang T, Xia Z, Berzofsky J Front Immunol. 2024; 15:1386243.

PMID: 38835757 PMC: 11148259. DOI: 10.3389/fimmu.2024.1386243.

A novel immunofluorescent test system for SARS-CoV-2 detection in infected cells.

Rak A, Matyushenko V, Prokopenko P, Kostromitina A, Polyakov D, Sokolov A PLoS One. 2024; 19(5):e0304534.

PMID: 38820303 PMC: 11142482. DOI: 10.1371/journal.pone.0304534.

Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.

Rocco J, Boswell K, Laidlaw E, Epling B, Anderson M, Serebryannyy L J Allergy Clin Immunol. 2024; 153(2):503-512.

PMID: 38344971 PMC: 10861932. DOI: 10.1016/j.jaci.2023.10.012.

Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in .

Safitri I, Sugijo Y, Puspasari F, Masduki F, Ihsanawati , Giri-Rachman E Vaccine X. 2024; 16:100443.

PMID: 38304876 PMC: 10832452. DOI: 10.1016/j.jvacx.2024.100443.

References

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

Hensel J, McAndrews K, McGrail D, Dowlatshahi D, LeBleu V, Kalluri R . Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci Rep. 2020; 10(1):18377. PMC: 7591473. DOI: 10.1038/s41598-020-75491-x. View

Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View

Hassan A, Kafai N, Dmitriev I, Fox J, Smith B, Harvey I . A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020; 183(1):169-184.e13. PMC: 7437481. DOI: 10.1016/j.cell.2020.08.026. View

Widge A, Rouphael N, Jackson L, Anderson E, Roberts P, Makhene M . Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2020; 384(1):80-82. PMC: 7727324. DOI: 10.1056/NEJMc2032195. View

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

Lavillegrand J, Garnier M, Spaeth A, Mario N, Hariri G, Pilon A . Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care. 2021; 11(1):9. PMC: 7804215. DOI: 10.1186/s13613-020-00798-x. View

Chen W . Promise and challenges in the development of COVID-19 vaccines. Hum Vaccin Immunother. 2020; 16(11):2604-2608. PMC: 7733917. DOI: 10.1080/21645515.2020.1787067. View

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

10.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

11.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

12.

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

13.

Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B . Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020; 130(10):5235-5244. PMC: 7524490. DOI: 10.1172/JCI138759. View

14.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

17.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

18.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

19.

Noval Rivas M, Ebinger J, Wu M, Sun N, Braun J, Sobhani K . BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. J Clin Invest. 2020; 131(2). PMC: 7810479. DOI: 10.1172/JCI145157. View

20.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View